CGEN boosted, GE busy, CERP slides

Compugen Ltd. (NasdaqCM: CGEN) prospered 16.32 percent in price Thursday to $4.49. Volume of 488,799 shares swamped its daily average of 76,429 shares. CGEN this week announced that administration of CGEN-15001 in an animal model of rheumatoid arthritis (RA) dramatically ameliorates the clinical symptoms of the disease. These results, combined with earlier results in an animal model of multiple sclerosis (MS), strongly support the therapeutic potential of CGEN-15001 for multiple autoimmune diseases and inflammatory conditions.

General Electric Company (NYSE: GE) was a volume leader Thursday, trading in 52,211,672 shares, falling short of its daily average of 59,748,000. Share prices for GE nipped up 1.60 percent to $17.77. GE Capital Media, Communications & Entertainment today announced that it will serve as Administrative Agent for a new $230MM senior secured credit facility for Lightower Fiber Networks, a leading fiber network and broadband service provider in the Northeast. GE Capital Markets served as lead left bookrunner on the transaction, which closed November 30

Cereplast Inc. (NasdaqCM: CERP) fell 10.46 percent Thursday to close at $3.51, on volume of 99,792 shares, better by a half than its daily average. CERP is a leading manufacturer of proprietary bio-based, compostable and sustainable plastics.

Tags: Biotech Stocks, CERP, CGEN, consumer discretionary, GE, healthcare, nasdaq, NYSE

This entry was posted on Thursday, December 16th, 2010 at 4:35 pm by Glenn and is filed under Consumer Discretionary Stocks, Health Care Stocks, Technology Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.